Synta Melanoma Data Coming in May

Xconomy Boston — 

Synta, the Lexington, MA-based developer of cancer drugs, said today it has completed enrolling 630 patients in a clinical trial of its lead product candidate for melanoma that has spread through the body. The company (NASDAQ: SNTA) has a goal of releasing results from the study in May. We profiled Synta’s efforts to develop this drug, elesclomol, last month.

By posting a comment, you agree to our terms and conditions.

Comments are closed.